1. Home
  2. RIGL vs DFP Comparison

RIGL vs DFP Comparison

Compare RIGL & DFP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • DFP
  • Stock Information
  • Founded
  • RIGL 1996
  • DFP 2013
  • Country
  • RIGL United States
  • DFP United States
  • Employees
  • RIGL N/A
  • DFP N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • DFP Investment Managers
  • Sector
  • RIGL Health Care
  • DFP Finance
  • Exchange
  • RIGL Nasdaq
  • DFP Nasdaq
  • Market Cap
  • RIGL 486.4M
  • DFP 418.2M
  • IPO Year
  • RIGL 2000
  • DFP N/A
  • Fundamental
  • Price
  • RIGL $17.09
  • DFP $20.25
  • Analyst Decision
  • RIGL Buy
  • DFP
  • Analyst Count
  • RIGL 5
  • DFP 0
  • Target Price
  • RIGL $34.80
  • DFP N/A
  • AVG Volume (30 Days)
  • RIGL 203.8K
  • DFP 56.2K
  • Earning Date
  • RIGL 11-07-2024
  • DFP 01-01-0001
  • Dividend Yield
  • RIGL N/A
  • DFP 6.73%
  • EPS Growth
  • RIGL N/A
  • DFP N/A
  • EPS
  • RIGL 0.22
  • DFP N/A
  • Revenue
  • RIGL $157,374,000.00
  • DFP N/A
  • Revenue This Year
  • RIGL $48.98
  • DFP N/A
  • Revenue Next Year
  • RIGL $14.43
  • DFP N/A
  • P/E Ratio
  • RIGL $77.18
  • DFP N/A
  • Revenue Growth
  • RIGL 21.65
  • DFP N/A
  • 52 Week Low
  • RIGL $7.48
  • DFP $15.45
  • 52 Week High
  • RIGL $29.82
  • DFP $19.31
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 30.82
  • DFP 42.45
  • Support Level
  • RIGL $16.68
  • DFP $20.00
  • Resistance Level
  • RIGL $19.80
  • DFP $20.64
  • Average True Range (ATR)
  • RIGL 1.53
  • DFP 0.19
  • MACD
  • RIGL -1.05
  • DFP -0.04
  • Stochastic Oscillator
  • RIGL 3.66
  • DFP 34.25

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.

Flaherty & Crumrine Pref&Inc Allocation is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.

Share on Social Networks: